News >

Atezolizumab, Cobimetinib Combo Active in mCRC

Jason Harris
Published: Monday, Mar 19, 2018

Johanna C. Bendell, MD

Johanna C. Bendell, MD
Atezolizumab (Tecentriq) in combination with cobimetinib (Cotellic) induced a 31% disease control rate (DCR) in patients with heavily-pretreated metastatic colorectal cancer (mCRC).

Bendell added that this combination is currently under evaluation in the randomized, phase III IMblaze370 (NCT02788279) trial. The 3-arm trial is comparing the cobimetinib/atezolizumab combination with atezolizumab monotherapy or single-agent regorafenib in patients with previously treated, unresectable locally advanced or metastatic colorectal adenocarcinoma. Investigators completed accrual about a year ago and data are scheduled to be released later this year.
Bendell JC, Bang YJ, Chee CE, et al. A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2018;36, (suppl 4S; abstr 560).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication